NEWS
By JIA-RUI CHONG and JIA-RUI CHONG,LOS ANGELES TIMES | August 13, 2006
LOS ANGELES -- An experimental AIDS drug, part of a new class of medicines known as integrase inhibitors, worked faster in controlling HIV than one of the most widely used drugs on the market, according to a preliminary study released yesterday. The integrase inhibitor, used in a drug cocktail with two others, cut the amount of HIV in 90 percent of patients to undetectable levels in 24 weeks. Much of the reduction occurred in the first four to eight weeks, said Dr. Robin Isaacs, who led the research.
NEWS
By JONATHAN D. ROCKOFF and JONATHAN D. ROCKOFF,SUN REPORTER | July 13, 2006
WASHINGTON -- AIDS and HIV patients, who have been seeking ever simpler treatments since struggling with a complicated regimen of as many as 25 pills a day a decade ago, can now take one daily pill. The new pill, Atripla, was approved yesterday by the Food and Drug Administration after an accelerated three-month review reflecting the major public health benefits anticipated by activists, doctors and health officials. Dr. Andrew C. von Eschenbach, the acting FDA commissioner, hailed the combination drug as a "landmark" that would "fundamentally change treatment" of acquired immune deficiency syndrome and the virus causing it. Since the difficult early days of treatment, AIDS cocktails have become simple enough that some patients swallow just a few medications a day. Atripla melds three widely prescribed drugs that have been available for several years and are often taken together.
NEWS
By MAGGIE FARLEY and MAGGIE FARLEY,LOS ANGELES TIMES | June 3, 2006
UNITED NATIONS -- A three-day AIDS conference set a goal yesterday of doubling spending to slow the spread of the disease, and 14 countries announced an airline ticket tax to fund greater access to AIDS drugs. The special session on HIV/AIDS was marked by political haggling over the mention of condoms, safe drug use and sex education. Delegates agreed to refer to condoms specifically, but language on drug use and sex education is couched in euphemisms. U.N. Secretary-General Kofi Annan pleaded with the assembled representatives, who included African presidents, foreign ministers from around the world and U.S. first lady Laura Bush, not to let politics derail future progress.
NEWS
By John Murphy and John Murphy,SUN FOREIGN STAFF | September 12, 2004
MBABANE, Swaziland - One recent morning, Themba Ginindza opened the door to this African kingdom's AIDS council headquarters and sighed in disgust. He had come to show off a new, high-tech computer system, the latest government effort to quell the wrath of HIV. With nearly 40 percent of its adults infected, the kingdom holds the grim distinction of having the highest HIV infection rate in the world. The computer system, paid for largely by international donations, could make the distribution of lifesaving AIDS drugs swift and efficient, allowing doctors and nurses even in rural areas to access medical records, order blood tests and request drug refills for thousands of patients.
NEWS
By Mary Curtius and Mary Curtius,LOS ANGELES TIMES | July 11, 2004
WASHINGTON - As the man in charge of the Bush administration's $15 billion plan to treat millions of HIV-infected people in underdeveloped nations, Randall Tobias might expect a hero's welcome at the International AIDS Conference opening today in Thailand. Instead, the U.S. global AIDS coordinator is likely to be greeted by the protests of activists opposed to the administration's policies and to Tobias. Tobias, some activists said, could expect a reception similar to the one given Health and Human Services Secretary Tommy G. Thompson at the last conference.
NEWS
By NEW YORK TIMES NEWS SERVICE | May 17, 2004
WASHINGTON -- The Bush administration announced a significant shift in its AIDS policy yesterday, expediting the approval process for generic and combination anti-retroviral drugs so they can be bought at lower prices and provided more efficiently and safely to millions of infected people in Africa and the Caribbean. The expedited process is also designed to encourage manufacturers to create a single pill, consisting of two or three licensed anti-retroviral drugs that are more potent when taken together.